PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT PART 03: RESEARCH METHODOLOGY PART 04: MARKET LANDSCAPE • Market ecosystem • Market characteristics • Market segmentation analysis PART 05: MARKET SIZING • Market definition • Market sizing 2017 • Market size and forecast 2017-2022 PART 06: FIVE FORCES ANALYSIS • Bargaining power of buyers • Bargaining power of suppliers • Threat of new entrants • Threat of substitutes • Threat of rivalry • Market condition PART 07: MARKET SEGMENTATION BY APPLICATION • Segmentation by application • Comparison by application • Neurological disorders – Market size and forecast 2017-2022 • Cancer – Market size and forecast 2017-2022 • Others – Market size and forecast 2017-2022 • Market opportunity by application PART 08: MARKET SEGMENTATION BY TECHNOLOGY • Segmentation by technology • Comparison by technology • Antisense/RNAi oligonucleotides – Market size and forecast 2017-2022 • Others – Market size and forecast 2017-2022 • Market opportunity by technology PART 09: CUSTOMER LANDSCAPE PART 10: REGIONAL LANDSCAPE • Geographical segmentation • Regional comparison • Americas – Market size and forecast 2017-2022 • EMEA – Market size and forecast 2017-2022 • APAC – Market size and forecast 2017-2022 • Key leading countries • Market opportunity PART 11: DECISION FRAMEWORK PART 12: DRIVERS AND CHALLENGES • Market drivers • Market challenges PART 13: MARKET TRENDS • Increasing M&A • Advances in DNA sequencing increases use of microfluidic techniques • Increasing drugs in pipeline PART 14: VENDOR LANDSCAPE • Overview • Landscape disruption PART 15: VENDOR ANALYSIS • Vendors covered • Vendor classification • Market positioning of vendors • Arrowhead Pharmaceuticals • GlaxoSmithKline • Ionis Pharmaceuticals • miRagen Therapeutics • Sarepta Therapeutics PART 16: APPENDIX • List of abbreviations Exhibit 01: Related market Exhibit 02: Market characteristics Exhibit 03: Market segments Exhibit 04: Market definition - Inclusions and exclusions checklist Exhibit 05: Market size 2017 Exhibit 06: Validation techniques employed for market sizing 2017 Exhibit 07: Global – Market size and forecast 2017-2022 ($ mn) Exhibit 08: Global – Year-over-year growth 2018-2022 (%) Exhibit 09: Five forces analysis 2017 Exhibit 10: Five forces analysis 2022 Exhibit 11: Bargaining power of buyers Exhibit 12: Bargaining power of suppliers Exhibit 13: Threat of new entrants Exhibit 14: Threat of substitutes Exhibit 15: Threat of rivalry Exhibit 16: Market condition - Five forces 2017 Exhibit 17: Application – Market share 2017-2022 (%) Exhibit 18: Comparison by application Exhibit 19: Neurological disorders – Market size and forecast 2017-2022 ($ mn) Exhibit 20: Neurological disorders – Year-over-year growth 2018-2022 (%) Exhibit 21: Cancer – Market size and forecast 2017-2022 ($ mn) Exhibit 22: Cancer – Year-over-year growth 2018-2022 (%) Exhibit 23: Others – Market size and forecast 2017-2022 ($ mn) Exhibit 24: Others – Year-over-year growth 2018-2022 (%) Exhibit 25: Market opportunity by application Exhibit 26: Technology – Market share 2017-2022 (%) Exhibit 27: Comparison by technology Exhibit 28: Antisense/RNAi oligonucleotides – Market size and forecast 2017-2022 ($ mn) Exhibit 29: Antisense/RNAi oligonucleotides – Year-over-year growth 2018-2022 (%) Exhibit 30: Others – Market size and forecast 2017-2022 ($ mn) Exhibit 31: Others – Year-over-year growth 2018-2022 (%) Exhibit 32: Market opportunity by technology Exhibit 33: Customer landscape Exhibit 34: Global – Market share by geography 2017-2022 (%) Exhibit 35: Regional comparison Exhibit 36: Americas – Market size and forecast 2017-2022 ($ mn) Exhibit 37: Americas – Year-over-year growth 2018-2022 (%) Exhibit 38: EMEA – Market size and forecast 2017-2022 ($ mn) Exhibit 39: EMEA – Year-over-year growth 2018-2022 (%) Exhibit 40: APAC – Market size and forecast 2017-2022 ($ mn) Exhibit 41: APAC – Year-over-year growth 2018-2022 (%) Exhibit 42: Key leading countries Exhibit 43: Market opportunity Exhibit 44: Cost of sequencing per genome in $ (2001-2015) Exhibit 45: Vendor landscape Exhibit 46: Landscape disruption Exhibit 47: Vendors covered Exhibit 48: Vendor classification Exhibit 49: Market positioning of vendors Exhibit 50: Arrowhead Pharmaceuticals overview Exhibit 51: Arrowhead Pharmaceuticals – Product segments Exhibit 52: Arrowhead Pharmaceuticals – Organizational developments Exhibit 53: Arrowhead Pharmaceuticals – Key offerings Exhibit 54: GlaxoSmithKline overview Exhibit 55: GlaxoSmithKline – Business segments Exhibit 56: GlaxoSmithKline – Organizational developments Exhibit 57: GlaxoSmithKline – Geographic focus Exhibit 58: GlaxoSmithKline – Segment focus Exhibit 59: GlaxoSmithKline – Key offerings Exhibit 60: Ionis Pharmaceuticals overview Exhibit 61: Ionis Pharmaceuticals – Business segments Exhibit 62: Ionis Pharmaceuticals – Organizational developments Exhibit 63: Ionis Pharmaceuticals – Segment focus Exhibit 64: Ionis Pharmaceuticals – Key offerings Exhibit 65: miRagen Therapeutics overview Exhibit 66: miRagen Therapeutics – Business segments Exhibit 67: miRagen Therapeutics – Organizational developments Exhibit 68: miRagen Therapeutics – Key offerings Exhibit 69: Sarepta Therapeutics overview Exhibit 70: Sarepta Therapeutics – Business segments Exhibit 71: Sarepta Therapeutics – Organizational developments Exhibit 72: Sarepta Therapeutics – Key offerings

Arrowhead Pharmaceuticals, GlaxoSmithKline, Ionis Pharmaceuticals, miRagen Therapeutics, Sarepta Therapeutics.